Skip to main content
PMC home page
Heart logoLink to Heart
. 2000 Jan;83(1):76–80. doi: 10.1136/heart.83.1.76

Postinfarction left ventricular remodelling: where are the theories and trials leading us?

Z Yousef 1, S Redwood 1, M Marber 1
PMCID: PMC1729255  PMID: 10618340

Full Text

The Full Text of this article is available as a PDF (84.3 KB).

Figure 1  .

Figure 1  

Open in a new tab

The law of Laplace.

Figure 2  .

Figure 2  

Open in a new tab

Signalling pathways associated with myocardial hypertrophy. A simplified overview of our current understanding of the intracellular signalling pathways leading to myocardial hypertrophy. Although the molecular events coupling membrane receptors to nuclear events have not been fully documented, three principal arms (with interpathway crosstalk) are described, each converging onto a common pathway (mitogen activated protein kinase cascade) which ultimately leads to the nucleus. Considerable work remains to be done to fully characterise the pathways before any potential therapeutic targets can be identified.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adinolfi A., Adinolfi M., Lessof Alpha-feto-protein during development and in disease. J Med Genet. 1975 Jun;12(2):138–151. doi: 10.1136/jmg.12.2.138. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Cleutjens J. P., Kandala J. C., Guarda E., Guntaka R. V., Weber K. T. Regulation of collagen degradation in the rat myocardium after infarction. J Mol Cell Cardiol. 1995 Jun;27(6):1281–1292. doi: 10.1016/s0022-2828(05)82390-9. [DOI] [PubMed] [Google Scholar]
  3. Goodfriend T. L., Elliott M. E., Catt K. J. Angiotensin receptors and their antagonists. N Engl J Med. 1996 Jun 20;334(25):1649–1654. doi: 10.1056/NEJM199606203342507. [DOI] [PubMed] [Google Scholar]
  4. Habib G. B., Heibig J., Forman S. A., Brown B. G., Roberts R., Terrin M. L., Bolli R. Influence of coronary collateral vessels on myocardial infarct size in humans. Results of phase I thrombolysis in myocardial infarction (TIMI) trial. The TIMI Investigators. Circulation. 1991 Mar;83(3):739–746. doi: 10.1161/01.cir.83.3.739. [DOI] [PubMed] [Google Scholar]
  5. Hirohata S., Kusachi S., Murakami M., Murakami T., Sano I., Watanabe T., Komatsubara I., Kondo J., Tsuji T. Time dependent alterations of serum matrix metalloproteinase-1 and metalloproteinase-1 tissue inhibitor after successful reperfusion of acute myocardial infarction. Heart. 1997 Sep;78(3):278–284. doi: 10.1136/hrt.78.3.278. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Hochman J. S., Choo H. Limitation of myocardial infarct expansion by reperfusion independent of myocardial salvage. Circulation. 1987 Jan;75(1):299–306. doi: 10.1161/01.cir.75.1.299. [DOI] [PubMed] [Google Scholar]
  7. Horie H., Takahashi M., Minai K., Izumi M., Takaoka A., Nozawa M., Yokohama H., Fujita T., Sakamoto T., Kito O. Long-term beneficial effect of late reperfusion for acute anterior myocardial infarction with percutaneous transluminal coronary angioplasty. Circulation. 1998 Dec 1;98(22):2377–2382. doi: 10.1161/01.cir.98.22.2377. [DOI] [PubMed] [Google Scholar]
  8. Iwaki K., Sukhatme V. P., Shubeita H. E., Chien K. R. Alpha- and beta-adrenergic stimulation induces distinct patterns of immediate early gene expression in neonatal rat myocardial cells. fos/jun expression is associated with sarcomere assembly; Egr-1 induction is primarily an alpha 1-mediated response. J Biol Chem. 1990 Aug 15;265(23):13809–13817. [PubMed] [Google Scholar]
  9. Janowitz W. R., Agatston A. S., Viamonte M., Jr Comparison of serial quantitative evaluation of calcified coronary artery plaque by ultrafast computed tomography in persons with and without obstructive coronary artery disease. Am J Cardiol. 1991 Jul 1;68(1):1–6. doi: 10.1016/0002-9149(91)90700-u. [DOI] [PubMed] [Google Scholar]
  10. Lang C. C., Choy A. M., Struthers A. D. Atrial and brain natriuretic peptides: a dual natriuretic peptide system potentially involved in circulatory homeostasis. Clin Sci (Lond) 1992 Nov;83(5):519–527. doi: 10.1042/cs0830519. [DOI] [PubMed] [Google Scholar]
  11. Levin E. R. Endothelins. N Engl J Med. 1995 Aug 10;333(6):356–363. doi: 10.1056/NEJM199508103330607. [DOI] [PubMed] [Google Scholar]
  12. Mahon N. G., O'rorke C., Codd M. B., McCann H. A., McGarry K., Sugrue D. D. Hospital mortality of acute myocardial infarction in the thrombolytic era. Heart. 1999 May;81(5):478–482. doi: 10.1136/hrt.81.5.478. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Marber M. S., Brown D. L., Kloner R. A. The open artery hypothesis: to open, or not to open, that is the question. Eur Heart J. 1996 Apr;17(4):505–509. doi: 10.1093/oxfordjournals.eurheartj.a014901. [DOI] [PubMed] [Google Scholar]
  14. McAlpine H. M., Morton J. J., Leckie B., Rumley A., Gillen G., Dargie H. J. Neuroendocrine activation after acute myocardial infarction. Br Heart J. 1988 Aug;60(2):117–124. doi: 10.1136/hrt.60.2.117. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Mulder P., Richard V., Derumeaux G., Hogie M., Henry J. P., Lallemand F., Compagnon P., Macé B., Comoy E., Letac B. Role of endogenous endothelin in chronic heart failure: effect of long-term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling. Circulation. 1997 Sep 16;96(6):1976–1982. doi: 10.1161/01.cir.96.6.1976. [DOI] [PubMed] [Google Scholar]
  16. Murry C. E., Jennings R. B., Reimer K. A. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation. 1986 Nov;74(5):1124–1136. doi: 10.1161/01.cir.74.5.1124. [DOI] [PubMed] [Google Scholar]
  17. Olivetti G., Capasso J. M., Sonnenblick E. H., Anversa P. Side-to-side slippage of myocytes participates in ventricular wall remodeling acutely after myocardial infarction in rats. Circ Res. 1990 Jul;67(1):23–34. doi: 10.1161/01.res.67.1.23. [DOI] [PubMed] [Google Scholar]
  18. Packer M., Bristow M. R., Cohn J. N., Colucci W. S., Fowler M. B., Gilbert E. M., Shusterman N. H. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med. 1996 May 23;334(21):1349–1355. doi: 10.1056/NEJM199605233342101. [DOI] [PubMed] [Google Scholar]
  19. Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol. 1992 Jul;20(1):248–254. doi: 10.1016/0735-1097(92)90167-l. [DOI] [PubMed] [Google Scholar]
  20. Pfeffer M. A., Braunwald E., Moyé L. A., Basta L., Brown E. J., Jr, Cuddy T. E., Davis B. R., Geltman E. M., Goldman S., Flaker G. C. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992 Sep 3;327(10):669–677. doi: 10.1056/NEJM199209033271001. [DOI] [PubMed] [Google Scholar]
  21. Pitt B., Segal R., Martinez F. A., Meurers G., Cowley A. J., Thomas I., Deedwania P. C., Ney D. E., Snavely D. B., Chang P. I. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE) Lancet. 1997 Mar 15;349(9054):747–752. doi: 10.1016/s0140-6736(97)01187-2. [DOI] [PubMed] [Google Scholar]
  22. Stillwell G. K. The Law of Laplace. Some clinical applications. Mayo Clin Proc. 1973 Dec;48(12):863–869. [PubMed] [Google Scholar]
  23. Struthers A. D. Ten years of natriuretic peptide research: a new dawn for their diagnostic and therapeutic use? BMJ. 1994 Jun 18;308(6944):1615–1619. doi: 10.1136/bmj.308.6944.1615. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Sugden P. H. Signaling in myocardial hypertrophy: life after calcineurin? Circ Res. 1999 Apr 2;84(6):633–646. doi: 10.1161/01.res.84.6.633. [DOI] [PubMed] [Google Scholar]
  25. Vannan M. A., Taylor D. J. Ventricular remodelling after myocardial infarction. Br Heart J. 1992 Sep;68(3):257–259. doi: 10.1136/hrt.68.9.257. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Watanabe T., Suzuki N., Shimamoto N., Fujino M., Imada A. Endothelin in myocardial infarction. Nature. 1990 Mar 8;344(6262):114–114. doi: 10.1038/344114a0. [DOI] [PubMed] [Google Scholar]
  27. White H. D., Cross D. B., Elliott J. M., Norris R. M., Yee T. W. Long-term prognostic importance of patency of the infarct-related coronary artery after thrombolytic therapy for acute myocardial infarction. Circulation. 1994 Jan;89(1):61–67. doi: 10.1161/01.cir.89.1.61. [DOI] [PubMed] [Google Scholar]
  28. White H. D., Norris R. M., Brown M. A., Brandt P. W., Whitlock R. M., Wild C. J. Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation. 1987 Jul;76(1):44–51. doi: 10.1161/01.cir.76.1.44. [DOI] [PubMed] [Google Scholar]
  29. Williams D. O., Braunwald E., Knatterud G., Babb J., Bresnahan J., Greenberg M. A., Raizner A., Wasserman A., Robertson T., Ross R. One-year results of the Thrombolysis in Myocardial Infarction investigation (TIMI) Phase II Trial. Circulation. 1992 Feb;85(2):533–542. doi: 10.1161/01.cir.85.2.533. [DOI] [PubMed] [Google Scholar]
  30. Yusuf S., Peto R., Lewis J., Collins R., Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335–371. doi: 10.1016/s0033-0620(85)80003-7. [DOI] [PubMed] [Google Scholar]

Articles from Heart are provided here courtesy of BMJ Publishing Group

RESOURCES